Navigation Links
Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
Date:2/11/2011

SAN DIEGO, Feb. 11, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the closing of a $20 million Series B Preferred Stock private placement financing.  This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included participation by existing investors; Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners, and Roche Venture Fund.  Conatus will use the proceeds to advance the clinical development of CTS-1027, a novel clinical-stage drug candidate the Company has licensed from F. Hoffman-La Roche, Ltd. and is the subject of multiple Phase 2 clinical trials in hepatitis C (HCV)-infected patients.  

As part of the financing, Louis Lacasse from AgeChem will join the Conatus Board of Directors. "We are very excited about joining such an elite group of investors to support the development of CTS-1027 which we believe could be a blockbuster drug for the treatment of HCV infections," said Louis Lacasse.

Continuing Board Directors are Paul Klingenstein from Aberdare Ventures, Shahzad Malik, M.D., from Advent Venture Partners, William Gerber, M.D., from Bay City Capital, and Marc Perret from Gilde Healthcare, and independent directors, David Hale and Hal Van Wart, Ph.D. Steven J. Mento, Ph.D., Co-founder, President and CEO of Conatus, will continue as Chairman of the Board.

Concurrent with the first closing of the Series B financing, Conatus also converted promissory bridge notes into Series B preferred stock.

The Series B financing will remain open for an additional period as other potential investors conclude their diligence.

"This financing enables Conatus to expand the clinical development of CTS-1027 as a cell-based antiviral for the treatment of HCV infections. We believe that CTS-1027 represents a novel approach to treating HCV disease and look forward to developing this drug candidate in the HCV-null responder population in combination with the existing standard of care drugs. We also believe that CTS-1027 may be an ideal candidate for use in combination with new antiviral drugs in future all oral treatments for HCV," said Steven J. Mento Ph.D.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology. Conatus' lead drug candidate, CTS-1027 is in multiple Phase 2 clinical trials for the treatment of hepatitis C virus (HCV).  Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
2. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
3. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
4. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
5. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... PLATTSBURGH, NY , Feb. 12, 2016 /PRNewswire/ - Demers Ambulances ... Florida to Okaloosa County ... 164 Type III ambulances and one LT2 van. Quality Emergency ... Demers dealer, is responsible for the sale.  This is the ... Benoit LaFortune , Executive Vice President at Demers. --> ...
(Date:2/12/2016)... 2016  Memorial Hermann Health System has teamed up ... to bring a one-of-a-kind experience to pediatric patients at ... such as 360-degree video and Google Cardboard, Howard was ... – giving the patients and their families an unexpected, ... caught on video . Memorial Hermann ...
(Date:2/12/2016)... 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ... Company will ring the Nasdaq Closing Bell at the ... at 4:00 p.m. ET on Tuesday, February ... Adrian Adams , will perform the honorary ... 4:00 p.m. ET.  A live webcast will be available ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The ... uncovers what he says are the real facts surrounding all those Bible stories. For ... and Sunday school teachers, and Yisrayl says there is more to these than just ...
(Date:2/12/2016)... ... , ... Planet Future is a Final Cut Pro X themed ... showcasing pictures, videos as well as text in an exciting cartoon environment. Planet Future ... a beautiful frame overlay. Pixel Film Studios makes editing easy; simply insert media into ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Dignity Health ... General Hospital Emergency Room –Mesa. The new facility is licensed under Dignity ... , “Dr. Bingham is an excellent leader and will ensure our new freestanding emergency ...
(Date:2/11/2016)... ... ... “ HEALING MIND : Five Steps to Ultimate Healing, Four Rooms ... teaches readers how to become their own therapist. Providing a useful step-by-step process for ... offers an understanding of how to heal one’s inner child using four archetypes of ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... use the action analytics leader’s population health solutions, MDinsight® and IndiGO®, for its ... the Atlanta-area healthcare system. Details of the contract were not disclosed. , As ...
Breaking Medicine News(10 mins):